Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALFAN vs ARALEN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
Treatment of mild to moderate acute malaria caused by Plasmodium falciparum and Plasmodium vivax (including chloroquine-resistant strains)
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive parasites,Extraintestinal amebiasis,Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label)
Adults: 500 mg orally once daily.
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
Terminal elimination half-life is 10-18 hours (mean 14 hours) in healthy adults, allowing twice-daily dosing.
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
Halofantrine is extensively metabolized in the liver, primarily via cytochrome P450 (CYP) 3A4, to its active metabolite N-desbutylhalofantrine. Both parent drug and metabolite are highly bound to plasma proteins.
Hepatic metabolism via CYP2C8, CYP3A4, and CYP2D6 to desethylchloroquine and other metabolites.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug; biliary/fecal elimination of metabolites approximately 20-30%.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
25-30% bound to serum albumin.
50-60%, primarily to albumin and α1-acid glycoprotein.
0.9-1.0 L/kg, indicating distribution into total body water.
50-100 L/kg; extensive tissue sequestration including erythrocytes, liver, spleen, and melanin-containing tissues like skin and retina.
Oral: 88-95%; rectal: 80-90%; intramuscular: 96%.
Oral: ~70-80% (variable due to first-pass metabolism); intravenous: 100%.
GFR 30-50 m L/min: 250 mg once daily; GFR <30 m L/min: 125 mg once daily.
Severe renal impairment (GFR <10 m L/min): reduce dose by 50% or increase dosing interval.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg once daily; Child-Pugh C: not recommended.
Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines available; contraindicated in severe hepatic disease or porphyria.
10 mg/kg orally once daily; maximum 500 mg/day.
Prophylaxis: 5 mg base/kg orally once weekly (max 300 mg base). Treatment: 10 mg base/kg orally initially, then 5 mg base/kg at 6, 24, and 48 hours (max 600 mg base total).
No specific adjustment; monitor renal function due to age-related decline.
Start at lower end of dosing range due to increased risk of adverse effects (e.g., QT prolongation, retinal toxicity); monitor renal function.
Cardiotoxicity: HALFAN prolongs the QT interval and can cause serious, life-threatening ventricular arrhythmias (e.g., torsade de pointes). Do not use in patients with pre-existing QTc prolongation, electrolyte disturbances (e.g., hypokalemia, hypomagnesemia), or those taking other drugs that prolong the QT interval. ECG monitoring is required before, during, and after therapy.
No FDA black box warning.
Cardiotoxicity: QTc interval prolongation; contraindicated in patients with conduction disorders or concurrent QT-prolonging drugs.,Hematologic: May cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.,Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain.,Hepatic: Use with caution in hepatic impairment.,Pregnancy: Not recommended (teratogenic in animal studies).,Drug interactions: Avoid with CYP3A4 inhibitors and QT-prolonging agents.
Retinopathy and irreversible retinal damage with prolonged use or high doses; requires baseline and periodic ophthalmologic exams,QT prolongation and ventricular arrhythmias, especially with concomitant QT-prolonging drugs or electrolyte abnormalities,Severe hypoglycemia including loss of consciousness,Neuropsychiatric effects including psychosis and suicidal ideation,Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency
Pre-existing QTc prolongation or congenital long QT syndrome,History of ventricular arrhythmias,Hypokalemia or hypomagnesemia,Concurrent use of drugs that prolong the QT interval (e.g., class IA/III antiarrhythmics, some antibiotics, antipsychotics),G6PD deficiency (relative),Pregnancy and breastfeeding (contraindicated in pregnancy)
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or known maculopathy,Known G6PD deficiency (relative, use with caution),Concomitant use with strong QT-prolonging drugs (e.g., quinidine, procainamide)
Take with a high-fat meal (e.g., full yogurt, burger, nuts) to increase absorption by up to 10-fold. Grapefruit juice may increase halofantrine levels; avoid concurrent use. Avoid alcohol due to additive QT-prolonging effects.
Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit alcohol intake to reduce risk of liver toxicity. Administer with food to decrease gastrointestinal irritation. Avoid antacids containing aluminum or magnesium; separate by at least 4 hours.
FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. First trimester: Avoid use due to potential teratogenic effects. Second and third trimesters: Limited data; risk of fetal harm cannot be ruled out. Use only if potential benefit justifies risk.
Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) at high doses. Second and third trimesters: possible ototoxicity and retinal toxicity; use only for malaria prophylaxis or treatment when benefit outweighs risk.
HALFAN is excreted in human milk. M/P ratio not reported. Due to potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or discontinue drug, taking into account importance of drug to mother.
Chloroquine is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Amounts are unlikely to cause adverse effects in nursing infants. The American Academy of Pediatrics considers chloroquine compatible with breastfeeding. Monitor infant for potential ocular effects.
No specific dosing adjustments recommended in pregnancy. Monitor for increased clearance and consider dose titration based on clinical response and side effects. Use lowest effective dose.
Increased volume of distribution and clearance during pregnancy may require higher doses for malaria prophylaxis (e.g., 400 mg base weekly) and treatment; therapeutic drug monitoring recommended for optimal dosing. No standard dose adjustment established; base dose on indication and clinical response.
Halofantrine (Halfan) is reserved for chloroquine-resistant Plasmodium falciparum malaria due to risk of fatal cardiotoxicity (QT prolongation, ventricular arrhythmias). Must obtain baseline ECG and monitor QTc; contraindicated if QTc >450 ms, family history of sudden death, or concurrent use of other QT-prolonging drugs. Administer with fatty food to enhance absorption, but food content may increase risk of arrhythmias. Do not repeat therapy within 6 weeks due to cumulative toxicity.
ARALEN HYDROCHLORIDE (chloroquine hydrochloride) is used for malaria prophylaxis and treatment, and for amebiasis. Monitor for retinal toxicity with long-term use; baseline and periodic ophthalmologic exams recommended. Caution in patients with hepatic disease, G6PD deficiency, or porphyria. May exacerbate psoriasis and myasthenia gravis. QT prolongation possible; avoid with other QT-prolonging drugs. Administer with food to reduce GI upset. For acute malaria, dose may be divided to improve tolerance. In severe malaria, use parenteral form with cardiac monitoring.
Take with a full meal high in fat to improve absorption.,Complete the full course even if symptoms improve.,Report immediately any chest pain, palpitations, fainting, or irregular heartbeat.,Avoid use with certain anti-malarials (e.g., quinine, mefloquine) and other drugs that affect heart rhythm.,Inform doctor if you have a personal or family history of heart problems, fainting, or electrolyte disturbances.,Do not use during pregnancy or breastfeeding unless specifically directed.
Take this medication exactly as prescribed; do not skip doses for malaria prophylaxis.,If vomiting occurs within 1 hour of a dose, contact your healthcare provider for instructions.,Report any vision changes, such as blurred vision or difficulty focusing, immediately.,Avoid alcohol and limit caffeine intake as they may increase gastrointestinal side effects.,Use effective contraception during treatment if you are of childbearing potential.,Do not take antacids or kaolin within 4 hours of this medication.,Seek medical attention if you experience signs of allergic reaction: rash, hives, swelling, or difficulty breathing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALFAN vs ARALEN HYDROCHLORIDE, answered by our medical review team.
HALFAN is a Antimalarial that works by HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.. ARALEN HYDROCHLORIDE is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALFAN and ARALEN HYDROCHLORIDE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALFAN is: Adults: 500 mg orally once daily.. The standard adult dose of ARALEN HYDROCHLORIDE is: Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HALFAN and ARALEN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HALFAN is classified as Category C. FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. First trimester: Avoid use due to potential teratogenic effects. Second and thi. ARALEN HYDROCHLORIDE is classified as Category C. Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.